Adverum Biotechnologies Inc. [NASDAQ: ADVM] closed the trading session at $12.91 on 08/25/20. The day’s price range saw the stock hit a low of $12.255, while the highest price level was $12.95. The company report on August 18, 2020 that Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock at a public offering price of $13.00 per share, which included the full exercise of the underwriters’ option to purchase up to an additional 2,175,000 shares of common stock. The gross proceeds to Adverum before deducting underwriting discounts and commissions and offering expenses payable by Adverum were approximately $216.8 million.
Goldman Sachs & Co. LLC, Cowen and Company, LLC, SVB Leerink LLC and Piper Sandler & Co. acted as joint book-running managers for the offering.
The stocks have a year to date performance of 12.07 percent and weekly performance of -4.58 percent. The stock has been moved at 0.00 percent over the last six months. The stock has performed -26.81 percent around the most recent 30 days and changed -38.58 percent over the most recent 3-months.
If compared to the average trading volume of 1.35M shares, ADVM reached to a volume of 1045963 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Adverum Biotechnologies Inc. [ADVM]:
Raymond James have made an estimate for Adverum Biotechnologies Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 26, 2020. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on May 13, 2020, representing the official price target for Adverum Biotechnologies Inc. stock. Previously, the target price had yet another raise from $13 to $21, while SunTrust kept a Buy rating on ADVM stock.
The Average True Range (ATR) for Adverum Biotechnologies Inc. is set at 1.10, with the Price to Sales ratio for ADVM stock in the period of the last 12 months amounting to 4151.00. The Price to Book ratio for the last quarter was 3.67, with the Price to Cash per share for the same quarter was set at 2.90.
ADVM stock trade performance evaluation
Adverum Biotechnologies Inc. [ADVM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.58. With this latest performance, ADVM shares dropped by -26.81% in over the last four-week period, additionally sinking by 0.00% over the last 6 months – not to mention a rise of 20.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADVM stock in for the last two-week period is set at 35.17, with the RSI for the last a single of trading hit 33.22, and the three-weeks RSI is set at 36.69 for Adverum Biotechnologies Inc. [ADVM]. The present Moving Average for the last 50 days of trading for this stock 18.42, while it was recorded at 12.91 for the last single week of trading, and 14.41 for the last 200 days.
Adverum Biotechnologies Inc. [ADVM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Adverum Biotechnologies Inc. [ADVM] shares currently have an operating margin of -27418.00. Adverum Biotechnologies Inc.’s Net Margin is presently recorded at -25794.40.
Return on Total Capital for ADVM is now -33.53, given the latest momentum, and Return on Invested Capital for the company is -31.87. Return on Equity for this stock declined to -34.29, with Return on Assets sitting at -29.57. When it comes to the capital structure of this company, Adverum Biotechnologies Inc. [ADVM] has a Total Debt to Total Equity ratio set at 18.55. Additionally, ADVM Total Debt to Total Capital is recorded at 15.64, with Total Debt to Total Assets ending up at 14.57. Long-Term Debt to Equity for the company is recorded at 16.18, with the Long-Term Debt to Total Capital now at 13.65.
Reflecting on the efficiency of the workforce at the company, Adverum Biotechnologies Inc. [ADVM] managed to generate an average of -$565,667 per employee.Adverum Biotechnologies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.30 and a Current Ratio set at 13.30.
Earnings per share (EPS) analysis for Adverum Biotechnologies Inc. [ADVM] stock
With the latest financial reports released by the company, Adverum Biotechnologies Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADVM.
Adverum Biotechnologies Inc. [ADVM]: Insider Ownership positions
There are presently around $1,116 million, or 86.00% of ADVM stock, in the hands of institutional investors. The top three institutional holders of ADVM stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7,801,641, which is approximately 7.273% of the company’s market cap and around 0.40% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 7,585,000 shares of the stock with an approximate value of $97.92 million in ADVM stocks shares; and VERSANT VENTURE MANAGEMENT, LLC, currently with $90.42 million in ADVM stock with ownership of nearly -0.91% of the company’s market capitalization.
Positions in Adverum Biotechnologies Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 93 institutional holders increased their position in Adverum Biotechnologies Inc. [NASDAQ:ADVM] by around 14,414,135 shares. Additionally, 52 investors decreased positions by around 8,104,951 shares, while 14 investors held positions by with 63,916,097 shares. The mentioned changes placed institutional holdings at 86,435,183 shares, according to the latest SEC report filing. ADVM stock had 33 new institutional investments in for a total of 7,575,062 shares, while 14 institutional investors sold positions of 1,300,665 shares during the same period.